Laflunimus (HR325) is a DHODH inhibitor that inhibits immunoglobulin IgM and IgG secretion in vitro and in vivo, with an IC50=2.5 µm, and exerts an immunosuppressive effect by interfering with pyrimidine metabolism, and is used in the study of neuralgia.
